Reuters logo
BRIEF-Shijiazhuang Yiling Pharmaceutical receives approval for chemical drug clinical trials
June 30, 2017 / 10:02 AM / 3 months ago

BRIEF-Shijiazhuang Yiling Pharmaceutical receives approval for chemical drug clinical trials

June 30 (Reuters) - Shijiazhuang Yiling Pharmaceutical Co Ltd :

* Says it has been granted approval for chemical drug clinical trials for XY0206 API and tablet issued by china food and drug administration

* XY0206 is used for treatment of leukemia and lung cancer and other malignant tumors

Source text in Chinese: goo.gl/iX5rJu

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below